Clinical Trial Update: Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating the combination of sorafenib tosylate and bevacizumab in advanced renal cell carcinoma, with results posted after completion …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Clear Cell Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-06-28